Welcome

- Audio for this event is available via ReadyTalk[®] Internet Streaming.
- No telephone line is required.
- Computer speakers or headphones are necessary to listen to streaming audio.
- Limited dial-in lines are available.
 Please send a chat message if needed.
- This event is being recorded.





Troubleshooting Audio

Audio from computer speakers breaking up?

Audio suddenly stop?


Click the <u>Refresh</u> icon –or– Click F5





Troubleshooting Echo


- Hear a bad echo on the call?
- Echo is caused by multiple browsers/tabs open to a single event (multiple audio feeds).
- Close all but one browser/tab and the echo will clear.



Example of Two Browsers/Tabs open in Same Event

Submitting Questions

Type questions in the "Chat with Presenter" section, located in the bottom-left corner of your screen.





PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Lisa Vinson, BS, BSN, RN

Project Manager

PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Hospital Inpatient Values, Incentives, and Quality Reporting (VIQR) Outreach and Education Support Contractor

September 28, 2017

Acronyms and Abbreviations

ACS	American College of Surgeons	ICD	International Classification of Diseases
ADT	Androgen Deprivation Therapy	ICU	Intensive Care Unit
AHRQ	Agency for Healthcare Research and Quality	IPPS	Inpatient Prospective Payment System
AJCC	American Joint Committee on Cancer	IQR	Inpatient Quality Reporting
AMA	American Medical Association	LabID	Laboratory-Identified
CAUTI	Catheter-Associated Urinary Tract Infection	LTCH	Long-Term Care Hospital
CDC	Centers for Disease Control and Prevention	MIF	Measure Information Form
CCN	CMS Certification Number	MRSA	Methicillin-Resistant Staphylococcus aureus
CDI	Clostridium difficile Infection	N/A	Not Available
CE	Continuing Education	NHSN	National Healthcare Safety Network
CLABSI	Central Line-Associated Bloodstream Infection	NQF	National Quality Forum
CMS	Centers for Medicare & Medicaid Services	OCM	Oncology Care Measure
CPT	Current Procedural Terminology	OQR	Outpatient Quality Reporting
CST	Cancer-Specific Treatment	PCH	PPS-Exempt Cancer Hospital
CY	Calendar Year	PCHQR	PPS-Exempt Cancer Hospital Quality Reporting
DACA	Data Accuracy and Completeness Acknowledgement	PPS	Prospective Payment System
EBRT	External Beam Radiotherapy	PR	Public Reporting
ECE	Extraordinary Circumstances Extension/ Exception	Q	Quarter
ED	Emergency Department	QIN	Quality Innovation Network
EOL	End of Life	QPP	Quality Payment Program
EPIC	Expanded Prostate Inventory Composite	RSAR	Risk-Standardized Admission Rate
FSR	Facility-Specific Report	RSEDR	Risk-Standardized ED Visit Rate
FY	Fiscal Year	SBRT	Stereotactic Body Radiation Therapy
HAI	Healthcare-Associated Infection	SCIP	Surgical Care Improvement Project
HCAHPS	Hospital Consumer Assessment of Healthcare	SIR	Standardized Infection Ratio
	Providers and Systems	SRS	Stereotactic Radiosurgery
HCP	Healthcare Personnel	SSI	Surgical Site Infection
HHS	US Department of Health and Human Services	TBD	To Be Determined
HQR	Hospital Quality Reporting	WBDCT	Web-Based Data Collection Tool

Purpose

This presentation will provide a practical overview of the changes impacting PCHQR Program participants due to the publication of the Fiscal Year (FY) 2018 Inpatient Prospective Payment System/Long-Term Care Hospital (IPPS/LTCH) Prospective Payment System (PPS) Final Rule.

Objectives

Upon completion of this program participants will be able to perform the following:

- Summarize the operational changes impacting the PCHQR Program
- Access and employ updated Program resources available on QualityNet and Quality Reporting Center
- Discuss updated PPS-Exempt Cancer Hospital Report elements that will be available on *QualityNet*

FY 2018 Final Rule

- Issued on August 2, 2017
 - Displayed at the Office of the Federal Register Public Inspection Desk until publication in the Federal Register on August 14, 2017
 - FY 2018 IPPS/LTCH PPS Final Rule—Display Copy
 - PCHQR Program rules on pages 1678–1735
- Published in Federal Register on August 14, 2017
 - FY 2018 IPPS/LTCH PPS Final Rule—PDF Version
 - PCHQR Program rules on pages 38411–38425

PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Summary of Operational Changes

Major Sections of Rule

- 1. Background
- 2. Criteria for Removal and Retention of PCHQR Program Measures
- 3. Retention and Removal of Previously Finalized Quality Measures for PCHs Beginning with the FY 2020 Program Year
- 4. New Quality Measures Beginning with the FY 2020 Program Year
- 5. Accounting for Social Risk Factors in the PCHQR Program
- 6. Possible New Quality Measure Topics for Future Years
- 7. Maintenance of Technical Specifications for Quality Measures
- 8. Public Display Requirements
- 9. Form, Manner, and Timing of Data Submission
- 10. Extraordinary Circumstances Exceptions (ECE) Policy Under the PCHQR Program

And, a special bonus feature!

Removal of the CST Measures

Beginning with diagnoses occurring as of January 1, 2018; therefore, last diagnosis cohort will be Quarter 4, 2017 with last reporting of data:

- August 15, 2018, for colon and breast chemotherapy measures
- February 15, 2019, for hormone measure

Due Date	Measure	Fiscal Year	Time Period
11/15/2017	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q1 2017 (1/1/17–3/31/17)
11/15/2017	Adjuvant Hormonal Therapy (NQF #0220)	2017	Q3 2016 (7/1/16–9/30/16)
02/15/2018	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q2 2017 (4/1/17–6/30/17)
02/15/2016	Adjuvant Hormonal Therapy (NQF #0220)	2017	Q4 2016 (10/1/16–12/31/16)
05/15/2018	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q3 2017 (7/1/17–9/30/17)
05/15/2016	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q1 2017 (1/1/17–3/31/17)
	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q4 2017 (10/1/17–12/31/17)
08/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q2 2017 (4/1/17–6/30/17)
	OCMs and EBRT (NQF #0382, #0383, #0384, #0389, #0390, and #1822)	2019	CY 2017 (1/1/17–12/31/17)
11/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q3 2017 (7/1/17–9/30/17)
02/15/2019	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q4 2017 (10/1/17–12/31/17)
08/15/2019	OCMs and EBRT (NQF #0382, #0383, #0384, #0389, #0390, and #1822)	2020	CY 2018 (1/1/18–12/31/18)

Addition of New Quality Measures for FY 2020 Program Year

	Clinical Process/Oncology Care Measures				
Short Name	NQF#	Measure Name			
N/A	0382	Oncology: Radiation Dose Limits to Normal Tissues			
N/A	0383	Oncology: Plan of Care for Pain—Medical Oncology and Radiation Oncology			
N/A	0384	Oncology: Medical and Radiation—Pain Intensity Quantified			
N/A	0390	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients			
N/A	0389	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients			
EOL-Chemo	0210	Proportion of Patients Who Died From Cancer Receiving Chemotherapy in the Last 14 Days of Life			
EOL-Hospice	0215	Proportion of Patients Who Died From Cancer Not Admitted to Hospice			
		Intermediate Clinical Outcome Measures			
Short Name	NQF#	Measure Name			
EOL-ICU	0213	Proportion of Patients Who Died From Cancer Admitted to the ICU in the Last 30 Days of Life			
EOL-3DH	0216	Proportion of Patients Who Died From Cancer Admitted to Hospice for Less than Three Days			

New Measures on QualityNet

Table 3: Clinical Process/Oncology Care Measures (OCMs)

NQF #	РСН #	Measure Name	Specifications Manual & Measure Information Forms	Data Collection Tool	Acceptable Method of Transmission
0210	PCH-32	Proportion of Patients Who Died From Cancer Receiving Chemotherapy in the Last 14 Days of Life	Measure information form under development	None. (This is a claims-based measure.)	This data will be submitted by CMS contractor on behalf of the PCH.
0215	PCH-34	Proportion of Patients Who Died From Cancer Not Admitted to Hospice	Measure information form under development	None. (This is a claims-based measure.)	This data will be submitted by CMS contractor on behalf of the PCH.

Table 4: Intermediate Clinical Outcome Measures

NQF #	РСН #	Measure Name	Specifications Manual & Measure Information Forms	Data Collection Tool	Acceptable Method of Transmission
0213	PCH-33	Proportion of Patients Who Died From Cancer Admitted to the ICU in the Last 30 Days of Life	Measure information form under development	None. (This is a claims-based measure.)	This data will be submitted by CMS contractor on behalf of the PCH.
0216	PCH-35	Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days	Measure information form under development	None. (This is a claims-based measure.)	This data will be submitted by CMS contractor on behalf of the PCH.

What About the "Old" Measures?

Table 3: Clinical Process/Oncology Care Measures (OCMs)

NQF#	PCH #	Measure Name	Specifications Manual & Measure Information Forms	Data Collection Tool	Acceptable Method of Transmission
0382	PCH-14	Oncology: Radiation dose limits to normal tissues	2017 Radiation dose limit measure information form 2017 Radiation dose limit algorithm (clean version) 2017 Radiation dose limit algorithm (population and sampling version)	2017 Radiation dose limit paper abstraction tool	Web-based data entry via <i>QualityNet Secure</i> <i>Portal</i>
0383	PCH-15	Oncology: Plan of care for pain	2017 Plan of care for pain measure information form 2017 Plan of care algorithm (clean version) 2017 Plan of care algorithm (population and sampling version)	for pain	Web-based data entry via <i>QualityNet Secure</i> <i>Porta</i> l
0384	PCH-16	Oncology: Pain intensity quantified	2017 Pain intensity quantified measure information form 2017 Pain intensity quantified algorithm (clean version) 2017 Pain intensity quantified algorithm (population and sampling version)	2017 Pain intensity quantified paper abstraction tool	Web-based data entry via <i>QualityNet Secure</i> <i>Porta</i> l

Previously Finalized and New Public Display Requirements

Measures	Time
 Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (Lymph Node Positive) Colon Cancer (NQF #0223)^X Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1cN0M0, or Stage IB—III Hormone Receptor Negative Breast Cancer (NQF #0559)^X 	2014 and subsequent years
Adjuvant Hormonal Therapy (NQF #0220) ^X	2015 and subsequent years
 Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382)* Oncology: Plan of Care for Pain—Medical Oncology and Radiation Oncology (NQF #0383) Oncology: Medical and Radiation—Pain Intensity Quantified (NQF #0384) Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients (NQF #0390) Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (NQF#0389) Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey (NQF #0166) 	2016 and subsequent years
 CLABSI (NQF #0139)** CAUTI (NQF #0138)** 	Deferred
External Beam Radiotherapy for Bone Metastases (NQF #1822)***	2017 and for subsequent years

^{*} Update newly finalized for display for the FY 2019 Program Year and subsequent years in the FY 2017 IPPS/LTCH PPS Final Rule (81 FR 57192); expanded cohort will be displayed as soon as feasible.

^{**} Deferral finalized in the FY 2017 IPPS/LTCH PPS Final Rule (81 FR 57192).

^{***}Measure finalized for public display in the FY 2017 IPPS/LTCH PPS Final Rule (81 FR 57192).

X Measure finalized for removal beginning the FY 2020 Program Year.

Practical Applications to Public Reporting of PCHQR Program Data

- CSTs
- OCMs and EBRT
- HCAHPS
- CLABSI and CAUTI
- SSI, CDI, MRSA, HCP, Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy

New end-of-life measures

Schedule for Public Reporting

Hospital Compare Release	Measures	Quarters Displayed
October 2017	PCH-1, PCH-2 PCH-3 PCH-29	Q3, Q4 2015 and Q1, Q2 2016 Q1, Q2, Q3, Q4 2015 Q1, Q2, Q3, Q4 2016
December 2017	PCH-1, PCH-2 PCH-3 PCH-29 PCH-14, PCH-15, PCH-16, PCH-17, PCH-18, and PCH-25	Q4 2015 and Q1, Q2, Q3 2016 Q2, Q3, Q4 2015 and Q1 2016 Q2, Q3, Q4 2016 and Q1 2017 Q1, Q2, Q3, Q4 2016
April 2018	PCH-1, PCH-2 PCH-3 PCH-29	Q1, Q2, Q3, Q4 2016 Q3, Q4 2015 and Q1, Q2 2016 Q3, Q4 2016 and Q1, Q2 2017
July 2018	PCH-1, PCH-2 PCH-3 PCH-29	Q2, Q3, Q4 2016 and Q1 2017 Q4 2015 and Q1, Q2, Q3 2016 Q4 2016 and Q1, Q2, Q3 2017
October 2018	PCH-1, PCH-2 PCH-3 PCH-29	Q3, Q4 2016 and Q1, Q2 2017 Q1, Q2, Q3, Q4 2016 Q1, Q2, Q3, Q4 2017
December 2018	PCH-1, PCH-2 PCH-3 PCH-29 PCH-14, PCH-15, PCH-16, PCH-17, PCH-18, and PCH-25	Q4 2016 and Q1, Q2, Q3 2017 Q2, Q3, Q4 2016 and Q1 2017 Q2, Q3, Q4 2017 and Q1 2018 Q1, Q2, Q3, Q4 2017*

^{*} Please note that the diagnosis cohort for NQF #0382 (PCH-14) is expanded in the data refreshed in December 2018 to include breast and rectal cancers, in addition to the previously included lung and pancreatic cancers.

Form, Manner, and Timing of Data Submission

WBDCT

- Quarterly submission of CSTs
- Annual submission of OCMs and EBRT, stratified by quarter (NQF #0382, #0383, #0384, #0389, #0390, and #1822)
- NHSN/CDC submission on behalf of PCHs
- Quarterly submission of CLABSI, CAUTI, SSI, CDI, and MRSA data
- Annual submission of Influenza Vaccination Coverage Among Healthcare Personnel (HCP)
- HCAHPS quarterly (via vendor)
- Claims-based measures
 - Outpatient chemotherapy
 - End-of-life measures
- DACA annually online via QualityNet

Extraordinary Circumstances Exceptions (ECE) Request Form

- Alignment with other CMS Programs
 - Extension of deadline to apply from 30 days following the occurrence
 - CMS may grant exception or extension due to CMS data-system issues
- ECE request form is available on the following websites:
 - QualityNet: PCHQR Program Resources
 - Quality Reporting Center. PCHQR Program Resources and Tools

Reporting Requirements for Areas Impacted by Hurricanes

CMS has issued communications granting an exception to PCHs located in specified counties, parishes, islands, and municipios in Texas, Florida, Louisiana, Puerto Rico, and the US Virgin Islands.

- For chart-abstracted data and NHSN HAI data:
 - November 2017 and February 2018 submission deadlines for discharge periods:
 - January 1, 2017 March 31, 2017 (Q1 2017) Colon Cancer/Breast Cancer
 - April 1, 2017 June 30, 2017 (Q2 2017) Colon Cancer/Breast Cancer
 - June 1, 2016 September 30, 2016 (Q3 2016) Adjuvant Hormonal Therapy
 - October 1, 2016 December 31, 2016 (Q4 2016) Adjuvant Hormonal Therapy
 - April1, 2017 June 30, 2017 (Q2 2017) CLABSI, CAUTI, SSI, CDI, MRSA
 - June 1, 2017 September 31, 2017 (Q3 2017) CLABSI, CAUTI, SSI, CDI, MRSA
- For HCP data:
 - o May 15, 2018 submission deadline for the 2017 2018 flu season:
 - October 1, 2017 March 31, 2018 (Q4 2017 through Q1 2018)
- For HCAHPS Survey data:
 - o October 2017 and January 2018 HCAHPS submission deadlines for discharge periods:
 - April 1, 2017 June 30, 2017 (Q2 2017)
 - July 1, 2017 September 30, 2017 (Q3 2017)

HCAHPS Survey

FY 2018 IPPS/LTCH PPS Final Rule (82 FR 38328 Through 38342)

- Existing HCAHPS Survey revised by refining the current Pain Management questions (HCAHPS questions 12, 13, and 14)
- Composite measure name updated from "Pain Management" to "Communication About Pain"
- New questions address how providers communicate with patients about pain while removing ambiguities in the wording or intent of the questions

HCAHPS Survey Questions

Previous Pain Management Questions	New Composite Measure Questions
During this hospital stay, did you need medicine for pain? ☐ Yes ☐ No	During this hospital stay, did you have any pain? ☐ Yes ☐ No
During this hospital stay, how often was your pain well controlled? □ Never □ Sometimes □ Usually □ Always	During this hospital stay, how often did hospital staff talk with you about how much pain you had? □ Never □ Sometimes □ Usually □ Always
During this hospital stay, how often did the hospital staff do everything they could to help you with your pain?	During this hospital stay, how often did hospital staff talk with you about how to treat your pain?

PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Updated Program Resources

Updates to QualityNet

PCHQR Program Web Pages

- Overview
- Measures
- Data Collection
- Data Submission
- Resources

Updated Resources

- Program Manual
- Measure Submission Deadlines by Due Date
- WBDCT Guideline by Due Date
- Relationship Matrix

Measure Submission Deadlines by Due Date

Due Date	Colon Cancer/ Breast Cancer	Adjuvant Hormonal Therapy	CLABSI/ CAUTI/SSI/ MRSA/CDI	HCP Flu Vac	HCAHPS	осм	EBRT	DACA
10/04/2017	N/A	N/A	N/A	N/A	Q2 2017 (4/1–6/30)	N/A	N/A	N/A
11/15/2017	Q1 2017 (1/1-3/31)	Q3 2016 (7/1–9/30)	Q2 2017 (4/1–6/30)	N/A	N/A	N/A	N/A	N/A
01/03/2018	N/A	N/A	N/A	N/A	Q3 2017 (7/1–9/30)	N/A	N/A	N/A
02/15/2018	Q2 2017 (4/1–6/30)	Q4 2016 (10/1–12/31)	Q3 2017 (7/1–9/30)	N/A	N/A	N/A	N/A	N/A
04/04/2018	N/A	N/A	N/A	N/A	Q4 2017 (10/1–12/31)	N/A	N/A	N/A
05/15/2018	Q3 2017 (7/1–9/30)	Q1 2017 (1/1-3/31)	Q4 2017 (10/1–12/31)	Q4 2017–Q1 2018 (10/1/17–3/31/18)	N/A	N/A	N/A	N/A
07/05/2018	N/A	N/A	N/A	N/A	Q1 2018 (1/1-3/31)	N/A	N/A	N/A
08/15/2018	Q4 2017 (10/1–12/31)	Q2 2017 (4/1–6/30)	Q1 2018 (1/1-3/31)	N/A	N/A	CY 2017 (1/1–12/31)	CY 2017 (1/1–12/31)	N/A
08/31/2018	N/A	N/A	N/A	N/A	N/A	N/A	N/A	For FY 2019
10/04/2018	N/A	N/A	N/A	N/A	Q2 2018 (4/1-6/30)	N/A	N/A	N/A
11/15/2018	N/A	Q3 2017 (7/1–9/30)	Q2 2018 (4/1–6/30)	N/A	N/A	N/A	N/A	N/A
01/03/2019	N/A	N/A	N/A	N/A	Q3 2018 (7/1–9/30)	N/A	N/A	N/A

WBDCT Guideline by Due Date

Due Date	Measure	Fiscal Year	Time Period
11/15/2017	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q1 2017 (1/1/17–3/31/17)
11/15/2017	Adjuvant Hormonal Therapy (NQF #0220)	2017	Q3 2016 (7/1/16–9/30/16)
02/45/2040	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q2 2017 (4/1/17–6/30/17)
02/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2017	Q4 2016 (10/1/16–12/31/16)
05/45/2040	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q3 2017 (7/1/17–9/30/17)
05/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q1 2017 (1/1/17–3/31/17)
	Colon Cancer (NQF #0223)/ Breast Cancer (NQF #0559)	2018	Q4 2017 (10/1/17–12/31/17)
08/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q2 2017 (4/1/17–6/30/17)
	OCMs and EBRT (NQF #0382, #0383, #0384, #0389, #0390, and #1822)	2019	CY 2017 (1/1/17–12/31/17)
11/15/2018	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q3 2017 (7/1/17–9/30/17)
02/15/2019	Adjuvant Hormonal Therapy (NQF #0220)	2018	Q4 2017 (10/1/17–12/31/17)
08/15/2019	OCMs and EBRT (NQF #0382, #0383, #0384, #0389, #0390, and #1822)	2020	CY 2018 (1/1/18–12/31/18)

Relationship Matrix of Program Measures by Years and Quarters

Oncology Care Measures	Program (Fiscal) Years	Reporting Periods- Calendar Year Quarters	Quarterly Data Submission Deadlines	Hospital Compare Release December 2016	Hospital Compare Releases April 2017, July 2017, and October 2017	Hospital Compare Release December 2017
NQF #0382	2016	1Q 2015	PRIOR			
(PCH-14)		2Q 2015		1Q2015-		
NOT HOOSE	2017	3Q 2015	PRIOR	4Q2015		
NQF #0383	30	4Q 2015				
(PCH-15)		1Q 2016				30-1-10-01-00-10-10-00-00-00-00-00-00-00-
NQF #0384	2018	2Q 2016	PRIOR			1Q2016-
(PCH-16)	2010	3Q 2016	TRIOR			4Q2016
(C) (T) (C)		4Q 2016				
NQF #0390		1Q 2017				
(PCH-17)	2019	2Q 2017	08/15/2018			
NOT #0200	2013	3Q 2017	00/13/2010			
NQF #0389	an i	4Q 2017	·			
(PCH-18)		1Q 2018				
	2020	2Q 2018	08/15/2019			
	2020	3Q 2018	00/13/2018			
	1	4Q 2018				

PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Updates to PPS-Exempt Cancer Hospital Reports

PCH Report Updates

- Use of superscripts on (N/A)1 and (N/A)2 [(N/A¹) and (N/A²)]
- Data tables will only display in the Program Years to which they apply
- Measure titles will be consistent with those in final rules.
- QINs will have access to PCH Reports
- "Diagnosis Cohort" will replace "Discharge Quarter" for CSTs
- The new, improved (N/A)1
- Patient days will appear for CDI and MRSA
- Population and sampling data will appear for OCMs, starting with 2016 data on FY 2018 PCH Report (retrospectively)
- "Update date" for HAIs will only update for current quarter being reported; this will **not** be retrospective

Use of "Diagnosis Cohort" for CSTs

Measure Set: Cancer Specific Measures					
-		Numerator	Denominator	Percent	
Measure: (NQF #0223) Adjuvan	t Chemotherapy Colon Cancer				
Last A CoS Update: 11/16/2016	Discharge Quarter: 01/01/2016 - 03/31/2016	3	4	75	
Last A CoS Update: 02/25/2017	Discharge Quarter: 04/01/2016 - 06/30/2016	1	2	50.0	
Last ACoS Update: 05/04/2017	Discharge Quarter: 07/01/2016 - 09/30/2016	1	1	100	
Last A CoS Update: (N/A)1	Discharge Quarter: 10/01/2016 - 12/31/2016	(N/A)1	(N/A)1	(N/A)1	

The New, Improved "N/A1"

- In the past (N/A1) displayed for the following:
 - Data not applicable
 - Any value equal to zero
- Now (N/A¹) will only display for data not applicable.

Measure Set: HAI	Measure: CL			
Oncology Location Type	Numerator	Denominator		
Discharge Quarter: 01/01/2016 - 03/31/2016	Last N	Last NHSN Update: 05/16/2017		
Medical-Surgical Critical Care	(N/A)1	141		
General Hematology/Oncology Ward	3	1112		
Discharge Quarter: 04/01/2016 - 06/30/2016	Last NHSN Update: 05/16/201			
Medical-Surgical Critical Care	(N/A)1	127		
General Hematology/Oncology Ward	6	1014		
Discharge Quarter: 07/01/2016 - 09/30/2016	Last N	Last NHSN Update: 05/16/2017		

Be Aware: N/A² Still Has Meaning Example of SCIP Measures in FY 2017 PCH Report

		Numerator	Denominator	Percent
Measure: (NQF #0527)	Prophylactic Antibiotics Received Within 1 Hou	r Prior to Surgic	al Incision	
	Discharge Quarter: 01/01/2015 - 03/31/2015	(N/A)2	(N/A)2	(N/A)2
	Discharge Quarter: 04/01/2015 - 06/30/2015	29	29	100
	Discharge Quarter: 07/01/2015 - 09/30/2015	30	30	100
	Discharge Quarter: 10/01/2015 - 12/31/2015	(N/A)2	(N/A)2	(N/A)2
Measure: (NQF #0528)	Prophylactic Antibiotic Selection for Surgical Pa	atients		
	Discharge Quarter: 01/01/2015 - 03/31/2015	(N/A)2	(N/A)2	(N/A)2
	Discharge Quarter: 04/01/2015 - 06/30/2015	24	29	82.8
	Discharge Quarter: 07/01/2015 - 09/30/2015	28	29	96.6
	Discharge Quarter: 10/01/2015 - 12/31/2015	(N/A)2	(N/A)2	(N/A)2

Patient Days for CDI and MRSA

- Actual patient days will display for CDI and MRSA.
- SIR will not display.

Measure Set: HAI					
		Numerator	Denominator	SIR	
Measure: Clostridium difficile Inf	ection (CDI)				
Last NHSN Update: 10/26/2016	Discharge Quarter: 01/01/2016 - 03/31/2016	3	(N/A)1	(N/A)1	
Last NHSN Update: 11/16/2016	Discharge Quarter: 04/01/2016 - 06/30/2016	5	(N/A)1	(N/A)1	
Last NHSN Update: 03/03/2017	Discharge Quarter: 07/01/2016 - 09/30/2016	2	(N/A)1	(N/A)1	
Last NHSN Update: 05/16/2017	Discharge Quarter: 10/01/2016 - 12/31/2016	(N/A)1	(N/A)1	(N/A)1	

CDI and MRSA Layout Will Be Similar to That for CLABSI and CAUTI

Measure Set: HAI		Measure: CLABSI		
Oncology Location Type	Numerator	Denominator		
Discharge Quarter: 01/01/2016 - 03/31/2016	Last NHSN Update: 05/16/2017			
Hematopoietic Stem Cell Transplant Ward	1	371		
General Hematology/Oncology Ward	1	1314		

Population and Sampling for OCMs

Current display for FY 2018

vieasure: (NGF #0384) Onco	logy: Pain Intensity Quantified			
	Discharge Quarter: 01/01/2016 - 03/31/2016	81	91	89
	Discharge Quarter: 04/01/2016 - 06/30/2016	82	110	75
	Discharge Quarter: 07/01/2016 - 09/30/2016	78	114	68
	Discharge Quarter: 10/01/2016 - 12/31/2016	90	111	81

Future display will mimic EBRT

	Population And Sampling					
	Sampling Frequency	Initial Patient Population	Sample Size	Numerator	Denominator	Percent
Measure: (NQF #1822) External Beam R	Radiotherapy	for Bone Metas	stases			
Discharge Quarter: 01/01/2015 - 03/31/2015	Quarterly	65	13	13	13	100
Discharge Quarter: 04/01/2015 - 06/30/2015	Quarterly	94	22	19	22	86
Discharge Quarter: 07/01/2015 - 09/30/2015	Quarterly	91	20	18	20	90
Discharge Quarter: 10/01/2015 - 12/31/2015	Quarterly	89	18	18	18	100

Date of "Last NHSN Update" Will Only Update for Most Recent Quarter

Measure Set: HAI		Measure: CLABSI
Oncology Location Type	Numerator	Denominator
Discharge Quarter: 01/01/2016 - 03/31/2016	Last N	HSN Update: 05/16/2017
Medical-Surgical Critical Care	(N/A)1	141
General Hematology/Oncology Ward	3	1112
Discharge Quarter: 04/01/2016 - 06/30/2016	Last N	HSN Update: 05/16/2017
Medical-Surgical Critical Care	(N/A)1	127
General Hematology/Oncology Ward	6	1014
Discharge Quarter: 07/01/2016 - 09/30/2016	Last N	HSN Update: 05/16/2017

PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Miscellaneous Notes

Outpatient Chemotherapy Measure National Confidential Reporting Period (Dry Run)

- Dry run of the Admissions and Emergency Department (ED)
 Visits for Patients Receiving Outpatient Chemotherapy
 measure (PCH-30/31) for the PCHQR Program has been
 extended through September 29, 2017.
- CMS has provided facilities with confidential, updated FSRs for the measure via the QualityNet Secure Portal.
- Detailed information about the measure and dry run is available on QualityNet at:
 - QualityNet > PPS-Exempt Cancer Hospitals > Measures > Chemotherapy Measure Dry Run
- CMS encourages facilities to review their measure results and ask questions about the measure during the dry run period.

 Send questions about the chemotherapy measure to <u>CMSChemotherapyMeasure@yale.edu</u>.

Important Upcoming Events

Currently Scheduled 2017 Webinars

- October 26: PCHQR Program: New End-of-Life Measures (American Society of Clinical Oncology [ASCO])
- November 16: PCHQR Program: Best Practices II
- December 14: PCHQR Program: The Year in Review and a Look Ahead

Important Upcoming Dates

Upcoming HQR Data Submissions

- October 4, 2017: Q2 2017 HCAHPS Survey
- November 15, 2017:
 - Q1 2017 chemo (breast and colon)
 - o Q3 2016 hormone
 - o Q2 2017 HAI

Important Upcoming Dates

Hospital Compare Key Dates

- October 2017
 - Contains:
 - 3Q 2015 through 2Q 2016 chemo data

 - 1Q 2015 through 4Q 2015 hormone data
 1Q 2016 through 4Q 2016 HCAHPS Survey data
 - Anticipated refresh October 25

December 2017

- o Contains:
 - 4Q 2015 through 3Q 2016 chemo data
 - 2Q 2015 through 1Q 2016 hormone data
 - 2Q 2016 through 1Q 2017 HCAHPS Survey data

 - 1Q 2016 through 4Q 2016 OCM data
 1Q 2016 through 4Q 2016 EBRT data
- Preview period scheduled October 2 through October 31
- Anticipated refresh December 20

Continuing Education Approval

This program has been pre-approved for 1.0 continuing education (CE) unit for the following professional boards:

National

Board of Registered Nursing (Provider #16578)

Florida

- Board of Clinical Social Work, Marriage & Family Therapy and Mental Health Counseling
- Board of Nursing Home Administrators
- Board of Dietetics and Nutrition Practice Council
- Board of Pharmacy

PLEASE NOTE: To verify CE approval for any other state, license, or certification, please check with your licensing or certification board.

CE Credit Process


- Complete the ReadyTalk® survey that will pop up after the webinar, or wait for the survey that will be sent to all registrants within the next 48 hours.
- After completion of the survey, click "Done" at the bottom of the screen.
- Another page will open that asks you to register in the HSAG Learning Management Center.
 - This is a separate registration from ReadyTalk[®].
 - Please use your personal email so you can receive your certificate.

Healthcare facilities have firewalls up that block our certificates.


CE Certificate Problems

- If you do not immediately receive a response to the email that you signed up with in the Learning Management Center, you have a firewall up that is blocking the link that was sent.
- Please go back to the New User link and register your personal email account.
 - Personal emails do not have firewalls.


CE Credit Process: Survey




CE Credit Process: Certificate



CE Credit Process: New User



CE Credit Process: Existing User



PCHQR Program: Practical Impacts of the FY 2018 IPPS/LTCH PPS Final Rule

Closing Remarks

Disclaimer

This presentation was current at the time of publication and/or upload onto the *Quality Reporting Center* and *QualityNet* websites. Medicare policy changes frequently. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.